Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2017.0156
• Publication Date: 2017-10-05T16:45:15Z
• Authors: Philippe E. Spiess; Neeraj Agarwal; Rick Bangs; Stephen A. Boorjian; Mark K. Buyyounouski; Peter E. Clark; Tracy M. Downs; Jason A. Efstathiou; Thomas W. Flaig; Terence Friedlander; Richard E. Greenberg; Khurshid A. Guru; Noah Hahn; Harry W. Herr; Christopher Hoimes; Brant A. Inman; Masahito Jimbo; A. Karim Kader; Subodh M. Lele; Joshua J. Meeks; Jeff Michalski; Jeffrey S. Montgo...; Lance C. Pagliaro; Sumanta K. Pal; Anthony Patterson; Elizabeth R. Plimack; Kamal S. Pohar; Michael P. Porter; Mark A. Preston; Wade J. Sexton; Arlene O. Siefker...; Guru Sonpavde; Jonathan Tward; Geoffrey Wile; Mary A. Dwyer; Lisa A. Gurski
• Keywords: 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Urinary Bladder Neoplasms; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Combined Modality Therapy; Neoplasm Staging; 3. Good health

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.